Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people find the Wegovy injection causes little more than a brief sting or mild pressure at the injection site — discomfort that typically lasts a few seconds. Clinical trial data published in the STEP 1 study in the New England Journal of Medicine recorded injection-site reactions in a minority of participants, and most described them as mild and transient. The shot is delivered via a pre-filled pen with a fine, short needle designed to sit just under the skin, which keeps the sensation manageable for the vast majority of people. Like any prescription medicine, semaglutide requires a clinical assessment before a prescriber can issue it — but pain at the injection site rarely turns out to be the barrier people expect.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial followed 1,961 adults over 68 weeks, giving it one of the largest bodies of close-monitored semaglutide safety data available. Injection-site reactions (a category that includes redness, bruising, pain and swelling) were recorded, but they were not among the most commonly reported side effects overall. That distinction went firmly to gastrointestinal symptoms: nausea, vomiting and diarrhoea were far more frequently noted than anything happening at the needle entry point. For most participants, the shot itself was a minor weekly event rather than a source of ongoing concern.
The NHS medicines page for semaglutide lists injection-site reactions as a known but uncommon occurrence, reinforcing that the clinical picture is reassuring. Where reactions did occur, they were typically short-lived. It is worth reading the Patient Information Leaflet supplied with your pen for the full list of reported frequencies, it gives the clearest picture of what was observed across thousands of doses.
If you want a broader overview of how semaglutide works and what to expect across treatment, the Wegovy treatment guide covers the licensed schedule and side-effect profile in one place. For people specifically dealing with soreness after a dose, there is dedicated practical advice on why the Wegovy shot might hurt more one week than another.
Subcutaneous injections go into the layer of fat just beneath the skin, not into muscle. That distinction matters: subcutaneous tissue has fewer pain receptors than muscle, which is why the sensation is usually described as a brief pinch rather than a sharp pain. The Wegovy pen's needle is fine-gauge and short by design.
Several technique factors influence how comfortable each injection feels. Cold medication stings more, so leaving the pen at room temperature for around 30 minutes before injecting helps. Injecting slowly and keeping the pen pressed against the skin until the full dose has delivered also reduces discomfort. Tensing the target area tends to increase the sensation; pinching the skin gently and relaxing the muscle beneath makes a practical difference.
Rotating injection sites is important for a different reason, repeated injections into the same small spot can cause localised skin changes (lipohypertrophy) over time, which can affect both comfort and how well the medicine is absorbed. The abdomen, thigh and upper arm are all licensed sites; moving between them gives each area time to recover. There is further detail on managing Wegovy injection discomfort if you want a step-by-step technique breakdown.
Occasionally people notice that the arm feels sore after a Wegovy injection more than other sites, often because the upper arm has less subcutaneous fat and the muscle underneath is more easily engaged if the technique is slightly off.
A second or two of mild stinging and perhaps some faint redness that fades within an hour: that is within normal range. Anything beyond that pattern deserves attention. Significant swelling, warmth, hard lumps that persist between doses, or pain that is getting steadily worse with each injection should prompt a conversation with the clinical team looking after your treatment.
It is also worth separating injection-site discomfort from other types of pain that can emerge on semaglutide. Some people notice generalised muscle ache, particularly early in treatment or around dose increases, this is a different phenomenon and is explored separately on the page about whether Wegovy can cause muscle pain. A smaller number of people report unusual skin sensitivity, which is covered in the guide to whether Wegovy can make your skin hurt. These are distinct from what happens at the needle site and have different explanations.
One thing our prescribers hear regularly: people worried before their first dose who then report that the injection was far less noticeable than expected. The pen arrives in plain, unbranded packaging via DPD with a tracking notification, and for many people, opening that box is more nerve-wracking than the injection itself turns out to be. If you have questions before or after starting, our support team is available seven days a week.
If cost is a consideration alongside these practical questions, the Wegovy cost page sets out what private treatment typically involves and what a transparent service price should include. And if you are still working out whether Wegovy is the right route for you, the treatment overview gives a balanced starting point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.